EMILY MIHAILESCU: Open Payments
NPI 1053970939 · BRIDGEPORT, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,147 in 104 payments from 13 companies in 2025. Trend: 2023 $317 · 2024 $1,069 · 2025 $2,147
Food & beverage: $2,147
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 28 | $441 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $387 |
| Alkermes, Inc. | 14 | $290 |
| E.R. Squibb & Sons, L.L.C. | 21 | $272 |
| Neurocrine BioSciences, Inc. | 9 | $208 |
| Otsuka America Pharmaceutical, Inc. | 2 | $150 |
| Axsome Therapeutics, Inc. | 1 | $125 |
| Indivior Inc. | 3 | $66 |
| Vanda Pharmaceuticals Inc. | 3 | $62 |
| Lundbeck LLC | 2 | $55 |
Products named: VRAYLAR, CAPLYTA, ARISTADA, COBENFY, INGREZZA, Auvelity, REXULTI, SUBLOCADE.
Industry payments across CT — which companies pay providers there.
